

Scientific Program

ATTD-ASIA is a groundbreaking expansion of ATTD – the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes assemble with the aim of sharing knowledge and developing collaborations.

Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence-based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.

[Interactive Program*Program Structure*](#)

*Subject to changes

Session Topics**

- CGM AS THE CORNERSTONE OF DIABETES MANAGEMENT
- CGM IN PRE-T2D AND EARLY T2D
- CLINICAL DECISION SUPPORT SYSTEMS (CDSS) AND APPS
- CLOSED LOOP
- COMBINED GLP1RA AND SGLT2
- COPING WITH OBESITY WITH OR WITHOUT DIABETES
- DIABETES & CVD
- DIABETES & PREGNANCY
- IMPLEMENTING NEW TECHNOLOGIES IN DIABETES MANAGEMENT
- INCRETINS AND THE REMISSION OF DIABETES
- LIFESTYLE MODIFICATIONS RELEVANT TO ASIA (DIET AND EXERCISE OPTIONS)
- MANAGING T2D IN PRIMARY CARE
- PEDIATRIC OBESITY AND DIABETES
- PRE T2D

- PRE-STAGE 3 T1D
- SCREENING PROGRAM AND PREVENTION T1D
- THERAPEUTIC CHOICES FOR OBESITY AND T2D
- TIGHT GLYCEMIC CONTROL
- TRAINING DIABETES TECHNOLOGISTS
- WEEKLY INSULIN

***Topic list as of 21 April 2024*

Ananta	Addala	USA	Solutions for equity: A call to action
Peter	Adolfsson	Sweden	Current use of connected pens
Stephanie	Amiel	UK	CGM detection of hypoglycemia in diabetes management
Lia	Bally	Switzerland	Virtual clinic for insulin therapy in type 2 diabetes
Katharine	Barnard-Kelly	UK	Consensus statement summary, navigating the maze of PROs
Tadej	Battelino	Slovenia	CGM derived data on weekly insulins
			CGM derived criteria for stage 2 type 1 diabetes
Richard	Bergenstal	USA	We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia
Mithun	Bhartia	India	Diabetes and sex life – the role of technology to improve quality of life
Bruce	Bode	USA	Management of glucose in the hospital with AID systems
Stefan	Bornstein	Germany	Islet Transplantation 2024
Emanuele	Bosi	Italy	Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool?
Charlotte	Boughton	UK	Cumulated experience with CamAPS in type 2 diabetes
Nataša	Bratina	Slovenia	Data on diabetes treatment in children below the age of six
Raffaella	Buzzetti	Italy	Antibody positivity in adult population
Anders	Carlson	USA	The use of CGM in prediabetes and obesity
			Use of AID in patients with type 2 diabetes
Eda	Cengiz	USA	Update on diabetes Female Technology (femtech)
Antonio	Ceriello	Italy	Weight and glycemic variability: Bad companions for CVD development in diabetes
Manoj	Chawla	India	Optimizing real time CGM in self pay markets
Patrik	Choudhary	UK	Implication of HypoMETRICS for reporting hypoglycemia in clinical trials
Mark	Clements	USA	Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior
Xavier	Cos	Spain	Use of CGM by the primary care providers
Amy	Criego	USA	CGM Success: Device start and ongoing data management to improve patient care
Tali	Cukierman-Yaffe	Israel	How to measure and monitor sarcopenia and frailty
			Diagnosis & monitoring of brain health in people with diabetes
Thomas	Danne	Germany	Worldwide progress achieving treatment targets in children with type 1 diabetes
Christophe	De Block	Belgium	Ketone continuous measurement – Is it needed?
Bastiaan	de Galan	The Netherlands	Impaired awareness of hypoglycemia

Sergio	di Molfetta	Italy	CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated
Klemen	Dovc	Slovenia	Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability
Celeste	Durnwold	USA	Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes?
Steven	Edelman	USA	• Top 10 tips to help people with diabetes (PwD) stay in range
			• With Jeremy Pettus – Rapid fire interpretations of CGM downloads
Laya	Ekhlaspour	USA	Beyond carbohydrate counting: Optimizing mealtime insulin dosing
Tara	Ettestad	USA	CGM guided or personalized nutrition
Chiara	Fabris	USA	• What do women want (and need)? Results from the large-scale IMAGINE survey
			• Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D
Leon	Farhy	USA	Diagnostic CGM
Andrea	Facchinetti	Italy	Digital twin technologies for treating diabetes
Deidre	Fitzgerald-Huges	Ireland	Shining a light on diabetic foot infections, development of novel photodynamic materials
Gregory	Forlenza	USA	Real-world data on hybrid closed-loop (HCL) in type 2 diabetes
Guido	Freckmann	Germany	International standard for evaluation of CGM systems: Approach of the IFCC
Juan	Frias	USA	Update on weekly insulin Efsitora
Satish	Garg	USA	Management options for treating obesity in type 1 diabetes patients
Michal	Gillon-Keren	Israel	Facilitate carb counting for people with diabetes
Francesco	Giorgino	Italy	Addressing glucose patterns in type 2 diabetes: Opportunities and challenges
Fernando	Gómez- Peralta	Spain	Connected insulin pens and caps: An expert's recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN)
Amit	Gupta	India	Challenges and opportunities in digital diabetes care in India
Michael	Haller	USA	Cost effectiveness of immune therapies in preserving beta cell function – Real world applications
Simon	Heller	UK	Should the classification of hypoglycemia be updated?
Irl	Hirsch	USA	What has the GMI taught us about A1C?
Roman	Hovorka	UK	Fully closed-loop in type 1 and type 2 diabetes
Daria	Igudesman	USA	Diet, microbiome, obesity and type 1 diabetes
Peter	Jacobs	USA	Unannounced meal detection algorithms: Can we eliminate manual meal boluses?
Laura	Jacobsen	USA	Immune therapy – Predicting responders/non-responders
Andrej	Janež	Slovenia	Incretins and taste
Johan	Jendle	Sweden	Interoperability of diabetes technology – Regulatory hurdle
Morten H	Jensen	Denmark	Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project
Shashank	Joshi	India	Artificial intelligence in diabetes care
Partha	Kar	UK	Widening clinical use of diabetes tech in the UK

Neal	Kaufman	USA	The importance and impact of family caregivers on a variety of outcomes for people with diabetes
Jothydev	Kesavadev	India	25 years of telemedicine Vs conventional care in diabetes: assessing vascular complications and quality of life
Kamlesh	Khunti	UK	Early intervention for type 2 diabetes in primary care
David	Klonoff	USA	Interoperability of diabetes technology – Academic view
Anna	Korsgaard Berg	Denmark	Skin problems caused by diabetes devices
Jernej	Kovac	Slovenia	Genetic background of obesity
Boris	Kovatchev	USA	Neural-Net artificial pancreas
Lori	Laffel	USA	Interventions to reduce health disparities in diabetes device use
Nebojsa	Lalic	Serbia	Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease
John	Leth	Denmark	The potential of open-source software in diabetes research
Alon	Liberman	Israel	Real world data from type 1 diabetes clinics
David	Maahs	USA	Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study
Julia	Mader	Austria	Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/training and awareness of HCP and PwD
Roberto	Mallone	France	Benign autoimmunity & progression to type 1 diabetes
Marco	Marigliano	Italy	Relationships between insulin delivery system, CGM satisfaction and glucometrics
Brynn	Marks	USA	Insulin delivery is automated, but the education is not: Mothering diabetes technology users
Thomas	Martens	USA	CGM guided insulin management
Chantal	Mathieu	Belgium	CGM derived data on weekly insulins
Barbara	McGowan	UK	Medical therapies for treatment of obesity
Laurel	Messer	USA	Technology pearls for professionals
Nicola	Minuto	Italy	Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough
V	Mohan	India	Innovating to use existing technologies under resourced settings
Antoinette	Moran	USA	Impact of CGM in East Africa, research and translation
Helen	Murphy	UK	Should everyone with type 1 diabetes be offered closed-loop during pregnancy?
Mary	Murphy	UK	What inclusion of quality PRO assessment in clinical trials means to people with diabetes
Hamidah	Nabakka	Uganda	Diabetes advocate perspective on diabetes technology in low-income countries
Max	Nieuwdorp	The Netherlands	A balanced view on microbiome in obesity
Revital	Nimri	Israel	Maximizing glycemic control with automated insulin delivery in young children
Kirsten	Nørgaard	Denmark	Low-dose glucagon to prevent hypoglycemia during exercise
			Effects of GLP1 in type 1 diabetes
Alexander	Olbrechts	Belgium	Interoperability of diabetes technology – A company's view
Rakesh	Parikh	India	Artificial Intelligence in the management of diabetes
Anne	Peters	USA	Pod use for closed-loop in T2D

Jeremy	Pettus	USA	With Steven Edelman – Rapid fire interpretations of CGM downloads
			Insulin resistance in type 1 diabetes: An underappreciated problem
Heiko	Peuscher	Germany	A survey on existing open-source projects in diabetes simulation
Moshe	Phillip	Israel	From dream to reality – The Automated Insulin Delivery (AID) system
Ivana	Rabbone	Italy	Technology in the changing management of diabetes in children
Dario	Rahelić	Croatia	Use of CGM in nutrition management in type 2 diabetes
Yves	Reznik	France	Closed-loop as home care for type 2 diabetes: The Close study
Michael	Rickels	USA	Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes
Camillo	Ricordi	USA	From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions
Michael	Riddell	Canada	CGM guided exercise
			Lessons learned from the ongoing type 1 diabetes exercise research Initiative
Samantha	Roberts	UK	Bringing science into lives: a NICE perspective
Teresa	Rodriguez-Calvo	Germany	Role of viruses in pathogenesis of type 1 diabetes
Leocadio	Rodríguez Mañas	Spain	Current treatment options for sarcopenia in the context of frail older people with diabetes
Julio	Rosenstock	USA	Update on weekly insulin Icodec: The way of the future
Banshi	Saboo	India	Welcome and introduction to Dtech symposium
Andrea	Scaramuzza	Italy	Real-world data in very young AHCL users – Comparison among different systems
Desmond	Schatz	USA	Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors
Oliver	Schnell	Germany	What PROs mean in routine clinical care
Eleanor	Scott	UK	CGM glucose trajectories associated with large and small for gestational age birthweight
Elisabeth	Selvin	USA	Diabetes and cognitive decline and dementia
			Should A1C still be a diagnostic criterion for diabetes in 2024?
Viral	Shah	USA	GLP-1RA and SGLT in type 1 diabetes
Jennifer	Sherr	USA	Teplizumab therapy in the real world
Gregg	Simonson	USA	CGM (GMI/TIR) as diabetes quality metrics
Alan	Sinclair	UK	Sarcopenia in people living with diabetes
Jay	Skyler	USA	Stem cell approaches to type 1 diabetes
Darja	Šmigoc Schweiger	Slovenia	Guided management of diabetes in female
Tim	Street	UK	Interoperability of diabetes technology – Patient's view
Stuart	Weinzimer	USA	Strategies to facilitate technology use in disadvantaged youth with diabetes
Emma	Wilmot	UK	Technology-supported behavior intervention in type 2 diabetes (STAND)
Jane	Yardley	Canada	Challenges of exercise in women with type 1 diabetes
Yariv	Yogev	Israel	Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?
Dessi	Zaharieva	USA	Translation of exercise guidelines into practical applications for type 1 diabetes